Achieve Life Sciences

SEATTLE and VANCOUVER, British Columbia, May 20, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV) a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced that additional analyses from its Phase 3 ORCA-3 study will be presented during an oral presentation at the 2025 American Thoracic Society (ATS) International Conference in San Francisco, CA. Presentation Details: Title: Cytisinicline Reduces Cravings and Nicotine Intake in People Who Smoke and Don't Quit Completely Session: C95 – Public Health and Policy Relevant Research Format: Mini Symposium Oral Presentation Date & Time: Tuesday, May 20, 2025; 2:15 PM – 4:15 PM EDT Location: 2025 ATS International Conference The oral presentation will highlight the unique benefit of cytisinicline treatment in clinical trials in reducing nicotine cravings which led to reduced nicotine intake, even in individuals who did not achieve complete smoking cessation.» Mehr auf globenewswire.com

Achieve Life Sciences, Inc. (NASDAQ:ACHV ) Q1 2025 Earnings Conference Call May 13, 2025 8:30 AM ET Company Participants Nicole Jones - Investor Relations Rick Stewart - Chief Executive Officer Cindy Jacobs - President and Chief Medical Officer Mark Oki - Chief Financial Officer Jaime Xinos - Chief Commercial Officer Conference Call Participants Gary Nachman - Raymond James Justin Walsh - Jones Trading John Vandermosten - Zacks Investment Research Operator Greetings. Welcome to Achieve Life Sciences First Quarter 2025 Earnings Conference Call and Webcast.» Mehr auf seekingalpha.com

Reiterates Planned Submission of an NDA for Cytisinicline to FDA in June 2025 Company to Host Conference Call at 8:30 AM EDT Today, Tuesday, May 13, 2025 SEATTLE and VANCOUVER, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced its financial results for first quarter 2025 and confirmed that it plans to submit the upcoming New Drug Application (NDA) for cytisinicline to the U.S. Food and Drug Administration (FDA) in June 2025. “The Achieve team is fully committed to finalizing the NDA for submission to the FDA next month.» Mehr auf globenewswire.com